COST-EFFECTIVENESS OF SUBCUTANEOUS VERSUS INTRAMUSCULAR INTERFERON BETA-1A IN PORTUGAL BASED ON THE FINDINGS OF COCHRANE COLLABORATION REVIEW OF FIRST-LINE TREATMENTS FOR RELAPSING-REMITTING MULTIPLE SCLEROSIS

被引：0

作者：

Silverio, N. ^{[1
]}

Sequeira, L. ^{[1
]}

Meletiche, D. ^{[2
]}

机构：

[1] Merck SA, Alges, Portugal

[2] EMD Serono, Rockland, ME USA

来源：

VALUE IN HEALTH | 2014年 / 17卷 / 07期

关键词：

D O I：

10.1016/j.jval.2014.08.897

中图分类号：

F [经济];

学科分类号：

02 ;

摘要：

PND43

引用

页码：A398 / A398

页数：1

共 50 条

[1] FINANCIAL AND CLINICAL IMPLICATIONS OF INTRAMUSCULAR VERSUS SUBCUTANEOUS INTERFERON BETA-1A IN PORTUGAL, BASED ON THE FINDINGS FROM THE COCHRANE COLLABORATION REVIEW OF FIRST-LINE TREATMENTS FOR RELAPSING-REMITTING MULTIPLE SCLEROSIS
Silverio, N.
Sequeira, L.
Meletiche, D.
VALUE IN HEALTH, 2014, 17 (07) : A396 - A396
[2] COST-EFFECTIVENESS OF FINGOLIMOD, TERIFLUNOMIDE, DIMETHYL FUMARATE AND INTRAMUSCULAR INTERFERON BETA-1A IN RELAPSING-REMITTING MULTIPLE SCLEROSIS
Zhang, X.
Hay, J. W.
VALUE IN HEALTH, 2014, 17 (03) : A59 - A60
[3] COST-EFFECTIVENESS AND BUDGET IMPACT ANALYSIS OF SUBCUTANEOUS INTERFERON BETA-1A FOR RELAPSING-REMITTING MULTIPLE SCLEROSIS IN SPAIN
Espallardo, O.
Crespo, C.
Polanco, C.
Nieves, D.
VALUE IN HEALTH, 2009, 12 (07) : A366 - A367
[4] COST-EFFECTIVENESS OF GLATIRAMER ACETATE AND INTERFERON BETA-1A FOR RELAPSING-REMITTING MULTIPLE SCLEROSIS, BASED ON THE COMBIRX STUDY
Darba, J.
Kaskens, L.
Sanchez-de la Rosa, R.
VALUE IN HEALTH, 2013, 16 (07) : A623 - A623
[5] Emerging Methods for Evaluating the Effectiveness of Intramuscular Interferon Beta-1a for Relapsing-Remitting Multiple Sclerosis
Foley, John F.
Barnes, Christopher J.
Nair, Kavita V.
JOURNAL OF MANAGED CARE PHARMACY, 2013, 19 (01): : S16 - S23
[6] COST-EFFECTIVENESS OF DACLIZUMAB VERSUS INTERFERON BETA-1A IN THE TREATMENT OF PATIENTS WITH RELAPSING-REMITTING MULTIPLE SCLEROSIS IN THE UNITED STATES
Rao, D.
Heidari, E.
Kamal, K. M.
Dashputre, A. A.
VALUE IN HEALTH, 2018, 21 : S206 - S206
[7] Effects of statins on intramuscular interferon beta-1a for relapsing-remitting multiple sclerosis
Rudick, R.
Pace, A.
Panzara, M.
Rani, S.
Schrock, J.
Calabresi, F.
Confavreux, C.
Galetta, S.
Lublin, F.
Radue, E. W.
Stuart, W.
Weinstock-Guttman, B.
Wynn, D.
MULTIPLE SCLEROSIS, 2007, 13 : S57 - S57
[8] Cost-effectiveness of alemtuzumab vs subcutaneous interferon beta-1a for treatment of active relapsing-remitting multiple sclerosis: payer perspective
Celestin, C.
Cutter, G. R.
Coles, A. J.
Reimers, A.
Margolin, D. H.
MULTIPLE SCLEROSIS JOURNAL, 2014, 20 : 72 - 72
[9] Cost-effectiveness analysis of ocrelizumab versus subcutaneous interferon beta-1a for the treatment of relapsing multiple sclerosis
Yang, Hongbo
Duchesneau, Emilie
Foster, Rebekah
Guerin, Annie
Ma, Esprit
Thomas, Nina P.
JOURNAL OF MEDICAL ECONOMICS, 2017, 20 (10) : 1056 - 1065
[10] COST-EFFECTIVENESS ANALYSIS OF PEGINTERFERON BETA-1A IN THE TREATMENT OF RELAPSING-REMITTING MULTIPLE SCLEROSIS IN SCOTLAND
Hernandez, L.
Guo, S.
Toro-Diaz, H.
Carroll, S.
Farooq, Syed S. F.
VALUE IN HEALTH, 2015, 18 (07) : A756 - A756

← 1 2 3 4 5 →